OpGen (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The firm presently has a $2.25 target price on the medical research company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 7.14% from the stock’s current price.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
OPGN has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of OpGen in a report on Tuesday, October 24th. ValuEngine lowered OpGen from a “sell” rating to a “strong sell” rating in a report on Thursday, January 25th.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. grew its position in OpGen Inc (NASDAQ:OPGN) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 at the end of the most recent quarter.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/15/opgen-opgn-raised-to-buy-at-zacks-investment-research.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.